Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background & Aims</h3><p>Infection with SARS-CoV-2 causes COVID-19, which has been characterized by fever, respiratory, and gastrointestinal symptoms as well as shedding of virus RNA into feces. We performed a systematic review and meta-analysis of published gastrointestinal symptoms and detection of virus in stool, and also summarized data from a cohort of patients with COVID-19 in Hong Kong.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We collected data from the cohort of patients with COVID-19 in Hong Kong (n=59; diagnosis from February 2 through Feb 29, 2020), and searched PubMed, Embase, Cochrane and three Chinese databases through March 11, 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, and abdominal pain or discomfort) using a random effects model.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Among the 59 patients with COVID-19 in Hong Kong, 15 patients (25.4%) had gastrointestinal symptoms and 9 patients (15.3%) had stool that tested positive for virus RNA. Stool viral RNA was detected in 38.5% and 8.7% among those with and without diarrhea, respectively (<em>P</em>=.02). The median fecal viral load was 5.1 log<sub>10</sub>cpm in patients with diarrhea vs 3.9 log<sub>10</sub>cpm in patients without diarrhea (<em>P</em>=.06). In a meta-analysis of 60 studies, comprising 4243 patients, the pooled prevalence of all gastrointestinal symptoms was 17.6% (95% CI, 12.3%–24.5%); 11.8% of patients with non-severe COVID-19 had gastrointestinal symptoms (95% CI, 4.1%–29.1%) and 17.1% of patients with severe COVID-19 had gastrointestinal symptoms (95% CI, 6.9%–36.7%). In the meta-analysis, the pooled prevalence of stool samples that were positive for virus RNA was 48.1% (95% CI, 38.3%–57.9%); of these samples, 70.3% of those collected after loss of virus from respiratory specimens tested positive for the virus (95% CI, 49.6%–85.1%).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>In an analysis of data from the Hong Kong cohort of patients with COVID-19 and a meta-analysis of findings from publications, we found that 17.6% of patients with COVID-19 had gastrointestinal symptoms. Virus RNA was detected in stool samples from 48.1% patients—even in stool collected after respiratory samples tested negative. Healthcare workers should therefore exercise caution in collecting fecal samples or performing endoscopic procedures in patients with COVID-19—even during patient recovery.</p>

Fecal viral shedding in COVID-19 patients: Clinical significance, viral load dynamics and survival analysis

Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients with COVID-19 Infection: A Systematic Review and Meta-analysis.

Characteristics of COVID-19 Patients With SARS-CoV-2 Positivity in Feces

Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China.

High anal swab viral load predisposes adverse clinical outcomes in severe COVID-19 patients

The Presence of SARS‐CoV‐2 RNA in the Feces of COVID‐19 Patients

Clinical Course and Factors Associated with Viral RNA Shedding and Radiologic Resolution in Patients with COVID-19: a Retrospective Study

Clinical Characteristics and Factors Associated with Long-Term Viral Excretion in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study

Delayed Clearance of Viral RNA in Sputum for Severity COVID-19 Patients with Initial High Viral Load

Clinical Features in Coronavirus Disease 2019 (COVID-19) Patients with Early Clearance and Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) RNA.

Clinical symptoms and faecal shedding of SARS-CoV-2 RNA among hospitalized COVID-19 patients: Implication for transmission

Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)

SARS-CoV-2 viral shedding characteristics and potential evidence for the priority for faecal specimen testing in diagnosis

Depicting SARS-CoV-2 Faecal Viral Activity in Association with Gut Microbiota Composition in Patients with COVID-19

The importance of fecal nucleic acid detection in patients with coronavirus disease (COVID‐19): A systematic review and meta‐analysis

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis

Longitudinal Virological Changes and Underlying Pathogenesis in Hospitalized COVID-19 Patients in Guangzhou, China

Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.

Impact of Age on Duration of Viral RNA Shedding in Patients with COVID-19.

Virus Shedding Dynamics in Asymptomatic and Mildly Symptomatic Patients Infected with SARS-CoV-2

Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study